Prospects for new antitubercular drugs

Current Opinion in Microbiology

Volumn 7, Issue 5, 2004, Pages 460-465

  Duncan, Ken ^a   Barry III, Clifton E ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIINFECTIVE AGENT; ETHAMBUTOL; ETHIONAMIDE; FATTY ACID; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MICROSPHERE; MOXIFLOXACIN; OFLOXACIN; POLYGLACTIN; POLYSACCHARIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; SQ 109; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL SURVIVAL; BACTERIUM CULTURE; BIOGENESIS; CHROMOSOME INSERTION; CLINICAL TRIAL; COLONY FORMING UNIT; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; CULTURE MEDIUM; DNA MICROARRAY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FATTY ACID SYNTHESIS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; RECURRENCE RISK; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; TRANSPOSON; TREATMENT FAILURE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; QUINOLONES; RIFAMYCINS; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; INSERTION SEQUENCES; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; TRANSPOSONS;

EID: 4644223350     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2004.08.011     Document Type: Review

References (58)

1. World Health Organisation: Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2004. ISBN 92 4 156264 1. 2004. Geneva, Switzerland.
2. E.L. Corbett, C.J. Watt, N. Walker, D. Maher, B.G. Williams, M.C. Raviglione, and C. Dye The growing burden of tuberculosis: global trends and interactions with the HIV epidemic Arch Intern Med 163 2003 1009 1021
3. M.A. Espinal The global situation of MDR-TB Tuberculosis 83 2003 44 51
4. R.J. O'Brien, and P.P. Nunn The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps Am J Respir Crit Care Med 163 2001 1055 1058
5. Global Alliance for TB Drug Development: Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis 2001, 81(Suppl 1):1-52.
6. D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C.R. Horsburgh, J. Horton, and A. Khan Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 2002 528 534
7. M. Weiner, W. Burman, A. Vernon, D. Benator, C.A. Peloquin, A. Khan, S. Weis, B. King, N. Shah, and T. Hodge Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine Am J Respir Crit Care Med 167 2003 1341 1347
8. R. Dietze, L. Teixeira, L.M. Rocha, M. Palaci, J.L. Johnson, C. Wells, L. Rose, K. Eisenach, and J.J. Ellner Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis Antimicrob Agents Chemother 45 2001 1972 1976
9. R.J. O'Brien Development of fluoroquinolones as first-line drugs for tuberculosis - at long last! Am J Respir Crit Care Med 168 2003 1266 1268
10. Tuberculosis Research Centre Chennai: Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002. 49: 27-38.
11. E.J. Alvirez-Freites, J.L. Carter, and M.H. Cynamon In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis Antimicrob Agents Chemother 46 2002 1022-1025.
12. Y. Hu, A.R. Coates, and D.A. Mitchison Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 653-657
13. N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R.J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice Antimicrob Agents Chemother 45 2001 3482 3486
14. T. Yoshimatsu, E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis Antimicrob Agents Chemother 46 2002 1875 1879
15. L. Fattorini, D. Tan, E. Iona, M. Mattei, F. Giannoni, L. Brunori, S. Recchia, and G. Orefici Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice Antimicrob Agents Chemother 47 2003 360 362
16. N. Veziris, C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo Antimicrob Agents Chemother 47 2003 3117 3122
17. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med 169 2004 421 426 A study that appears to suggest that replacement of isoniazid with moxifloxacin might shorten the treatment regimen.
18. J. Grosset, C. Truffot-Pernot, C. Lacroix, and B. Ji Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice Antimicrob Agents Chemother 36 1992 548 551
19. A. Jindani, C.J. Dore, and D.A. Mitchison Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days Am J Respir Crit Care Med 167 2003 1348 1354
20. G. Valerio, P. Bracciale, V. Manisco, M. Quitadamo, G. Legari, and S. Bellanova Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results J Chemother 15 2003 66 70
21. R.J. O'Brien Studies of the early bactericidal activity of new drugs for tuberculosis: a help or a hindrance to antituberculosis drug development? Am J Respir Crit Care Med 166 2002 3 4
22. R.D. Gosling, L.O. Uiso, N.E. Sam, E. Bongard, E.G. Kanduma, M. Nyindo, R.W. Morris, and S.H. Gillespie The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis Am J Respir Crit Care Med 168 2003 1342 1345 Demonstration of effectiveness of moxifloxacin in man in early stage of treatment.
23. Pletz MWR, A. De Roux, A. Roth, K.H. Neumann, H. Mauch, and H. Lode Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study Antimicrob Agents Chemother 48 2004 780 782
24. A.F.B. Cheng, W.W. Yew, E.W.C. Chan, M.L. Chin, M.M.M. Hui, and R.C.Y. Chan Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates Antimicrob Agents Chemother 48 2004 596 601
25. S.K. Park, W.C. Lee, D.H. Lee, C.D. Mitnick, L. Han, and K.J. Seung Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea Int J Tuberc Lung Dis 8 2004 361 368
26. C.K. Stover, P. Warrener, D.R. VanDevanter, D.R. Sherman, T.M. Arain, M.H. Langhorne, S.W. Anderson, J.A. Towell, Y. Yuan, and D.N. McMurray A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 2000 962 966
27. Global Alliance for TB Drug Development: 2002-2003 Annual Report. 2003.
28. Barry CE III, Boshoff H, Dowd C: Prospects for the clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004, in press.
29. R.E. Lee, M. Protopopova, E. Crooks, R.A. Slayden, M. Terrot, and C.E. Barry III Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates J Comb Chem 5 2003 172 187 Modern combinatorial chemistry approach to generate large library of ethambutol analogues from which a more potent drug candidate has been selected.
30. Hanrahan C, Bogatcheva E, Protopopova M, Nikonenko B, Samala R, Jia L: Development of second generation antibiotics for treatment of tuberculosis [abstract] F-2136 43rd ICAAC 14-17 September 2003.
31. M. Dutt, and G.K. Khuller Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles J Antimicrob Chemother 47 2001 829 835
32. Q. Ul-Ain, S. Sharma, and G.K. Khuller Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis Antimicrob Agents Chemother 47 2003 3005 3007 Study demonstrating that intermittent chemotherapy with drugs trapped in polyactide-coglycolide microspheres may be possible.
33. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J Antimicrob Chemother 52 2003 981 986
34. Qurrat-ul-Ain, S. Sharma, G.K. Khuller, and S.K. Garg Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects J Antimicrob Chemother 51 2003 931 938
35. R. Pandey, and G.K. Khuller Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers J Antimicrob Chemother 53 2004 635 640
36. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharm Res 18 2001 1315 1319
37. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm Res 18 2001 1405 1410
38. N. Tsapis, D. Bennett, K. O'Driscoll, K. Shea, M.M. Lipp, K. Fu, R.W.D. Clarke, D. Yamins, J. Wright, and C.A. Peloquin Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis 83 2003 379 385
39. K. Duncan Progress in TB drug development and what is still needed Tuberculosis 83 2003 201 207
40. Barry CE III, Duncan K: Tuberculosis - strategies towards anti-infectives for a chronic disease. Drug Discovery Today - Therapeutic Strategies 2004, in press.
41. S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S.V. Gordon, K. Eiglmeier, S. Gas, and C.E. Barry III Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 393 1998 537 544
42. R.D. Fleischmann, D. Alland, J.A. Eisen, L. Carpenter, O. White, J. Peterson, R. DeBoy, R. Dodson, M. Gwinn, and D. Haft Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains J Bacteriol 184 2002 5479 5490 Analysis of genome sequence of a recent clinical isolate of Mycobacterium tuberculosis and comparison with laboratory strain H37Rv reveals a higher than expected level of genetic polymorphisms.
43. J.C. Camus, M.J. Pryor, C. Medigue, and S.T. Cole Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv Microbiology 148 2002 2967 2973
44. S.T. Cole, K. Eiglmeier, J. Parkhill, K.D. James, N.R. Thomson, P.R. Wheeler, N. Honore, T. Garnier, C. Churcher, and D. Harris Massive gene decay in the leprosy bacillus Nature 409 2001 1007 1011
45. S.T. Cole Comparative mycobacterial genomics as a tool for drug target and antigen discovery Eur Respir J Suppl 36 2002 78s 86s
46. M. Marmiesse, P. Brodin, C. Buchrieser, C. Gutierrez, N. Simoes, V. Vincent, P. Glaser, S.T. Cole, and R. Brosch Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex Microbiol 150 2004 483 496
47. Warner DF, Mizrahi V: Mycobacterial genetics in target validation. Drug Discovery Today: Technologies 2004, in press.
48. C.M. Sassetti, D.H. Boyd, and E.J. Rubin Comprehensive identification of conditionally essential genes in mycobacteria Proc Natl Acad Sci USA 98 2001 12712 12717
49. C.M. Sassetti, D.H. Boyd, and E.J. Rubin Genes required for mycobacterial growth defined by high density mutagenesis Mol Microbiol 48 2003 77 84 Use of transposon site hybridisation to identify all the essential genes for in vitro growth of Mycobacterium tuberculosis.
50. C.M. Sassetti, and E.J. Rubin Genetic requirements for mycobacterial survival during infection Proc Natl Acad Sci USA 100 2003 12989 12994 Use of transposon site hybridisation to identify genes necessary for growth or survival of Mycobacterium tuberculosis in vivo.
51. M.I. Voskuil, D. Schnappinger, K.C. Visconti, M.I. Harrell, G.M. Dolganov, D.R. Sherman, and G.K. Schoolnik Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program J Exp Med 198 2003 705 713
52. P.J. Brennan Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis Tuberculosis 83 2003 91 97
53. S. Khasnobis, V.E. Escuyer, and D. Chatterjee Emerging therapeutic targets in tuberculosis: post-genomic era Expert Opin Ther Targets 6 2002 21 40
54. T.L. Lowary Recent progress towards the identification of inhibitors of mycobacterial cell wall polysaccharide biosynthesis Mini Rev Med Chem 3 2003 689 702
55. E.K. Schroeder, N. de Souza, D.S. Santos, J.S. Blanchard, and L.A. Basso Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis Curr Pharm Biotechnol 3 2002 197 225
56. K. Sharma, P. Chopra, and Y. Singh Recent advances towards identification of new drug targets for Mycobacterium tuberculosis Expert Opin Ther Targets 8 2004 79 93
57. Duncan K: Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 2004, in press.
58. Boshoff HIM, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE III: The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004, in press; DOI: 10.1074/jbc.M406796200.